Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?

BACKGROUND: Sargramostim [recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF)] was approved by US FDA in 1991 to accelerate bone marrow recovery in diverse settings of bone marrow failure and is designated on the list of FDA Essential Medicines, Medical Countermeasures, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazarus, Hillard M., Ragsdale, Carolyn E., Gale, Robert Peter, Lyman, Gary H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416151/
https://www.ncbi.nlm.nih.gov/pubmed/34484202
http://dx.doi.org/10.3389/fimmu.2021.706186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416151/
https://www.ncbi.nlm.nih.gov/pubmed/34484202
http://dx.doi.org/10.3389/fimmu.2021.706186

Ejemplares similares